It is also important to note that, in cancer cells, a synergism was reported when an NK-1R antagonist was co-administered with cytostatic drugs (e.g., cisplatin, ifosfamide, mitomycin, adriamycin and doxorubicin); however, this effect was not observed in human fibroblasts, and when the latter cells were treated with an NK-1R antagonist, prior to exposure to cytostatic drugs, human fibroblasts were partially protected from these drugs [16]. Here, TACR1 is linked to cancer.